Why the study?
Do prostaglandin synthesis inhibitors alter coronary vascular resistance in patients with ischemic heart disease?
Population
48 patients with ischemic heart disease (IHD)
Comparison
Atrial pacing to angina and oral administration… vs Baseline
Design
Cohort
Authors
Loading...
No practice change for NSAID selection in IHD; leaves open indomethacin-specific coronary effects requiring prospective confirmation.
Do prostaglandin synthesis inhibitors alter coronary vascular resistance in patients with ischemic heart disease?
Indomethacin increases coronary vascular resistance in patients with ischemic heart disease through a direct drug effect rather than via inhibition of locally formed prostaglandins.
Edlund et al. (1985) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: